Marksans Pharma Limited
NSE: MARKSANS · Pharmaceuticals
Snapshot
Unlock Marksans Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Marksans Pharma Limited is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations across a wide range of therapeutic areas. The company operates globally and provides contract research and manufacturing services to third-party clients.
Business Model
The company generates revenue through the sale of generic pharmaceutical products and by providing contract research and manufacturing services. It leverages its manufacturing capabilities to distribute products across diverse therapeutic segments worldwide.
- Incorporation Year:1992
Growth Outlook
Growth is driven by the expansion of its generic product portfolio and the scaling of its contract research and manufacturing services. The company continues to focus on diverse therapeutic areas to capture global market demand.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market often leads to pricing erosion and margin compression.
- Supply Chain Disruptions. Dependence on external suppliers for active pharmaceutical ingredients and raw materials may impact production timelines and costs.
- Currency Volatility. As a global player, the company is exposed to fluctuations in foreign exchange rates which can impact profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Marksans Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,172 Cr
TTM · consolidated
NET PROFIT
₹521 Cr
TTM · consolidated
EPS
₹11.41
TTM · consolidated
RETURN ON EQUITY
31.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
39.6%
TTM · consolidated
P/E
28.5×
Q1 FY27 · consolidated
EV/EBITDA
18.6x
Q1 FY27 · consolidated
EBITDA MARGIN
25.7%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Marksans Pharma LimitedMARKSANS | ₹15,756 Cr | 28.5× | 18.57 | 57.4% | 25.7% | 31.9% | 39.6% | +95.4% |
Jubilant Pharmova Ltd.JUBLPHARMA | ₹16,852 Cr | 45.0× | 14.55 | 16.3% | 15.0% | 5.3% | 6.5% | -10.2% |
AstraZenca Pharma India Ltd.ASTRAZEN | ₹16,765 Cr | 88.9× | 63.65 | 31.1% | 10.5% | 20.6% | 25.7% | -34.6% |
Alembic Pharmaceuticals Ltd.APLLTD | ₹16,598 Cr | 23.1× | 14.42 | 14.1% | 15.8% | 12.7% | 14.3% | -9.8% |
Concord Biotech Ltd.CONCORDBIO | ₹16,323 Cr | 52.7× | 37.08 | -6.7% | 39.7% | 14.2% | 18.5% | -15.9% |
NATCO Pharma Ltd.NATCOPHARM | ₹15,002 Cr | 12.9× | 11.51 | -20.7% | 38.7% | 13.6% | 13.5% | +1.8% |
As of Q1 FY27
Financials
Marksans Pharma Limited
NSE: MARKSANS · Pharmaceuticals
Snapshot
Unlock Marksans Pharma Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Marksans Pharma Limited is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic formulations across a wide range of therapeutic areas. The company operates globally and provides contract research and manufacturing services to third-party clients.
Business Model
The company generates revenue through the sale of generic pharmaceutical products and by providing contract research and manufacturing services. It leverages its manufacturing capabilities to distribute products across diverse therapeutic segments worldwide.
- Incorporation Year:1992
Growth Outlook
Growth is driven by the expansion of its generic product portfolio and the scaling of its contract research and manufacturing services. The company continues to focus on diverse therapeutic areas to capture global market demand.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities like the US FDA.
- Pricing Pressure. Intense competition in the generic pharmaceutical market often leads to pricing erosion and margin compression.
- Supply Chain Disruptions. Dependence on external suppliers for active pharmaceutical ingredients and raw materials may impact production timelines and costs.
- Currency Volatility. As a global player, the company is exposed to fluctuations in foreign exchange rates which can impact profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Marksans Pharma Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹3,172 Cr
TTM · consolidated
NET PROFIT
₹521 Cr
TTM · consolidated
EPS
₹11.41
TTM · consolidated
RETURN ON EQUITY
31.9%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
39.6%
TTM · consolidated
P/E
28.5x
Q1 FY27 · consolidated
EV/EBITDA
18.6x
Q1 FY27 · consolidated
EBITDA MARGIN
25.7%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27